AKF-PD (lot No. 20190810) was purchased from Hai
kou Pharma (Hai
kou, China). ATP assays were obtained from Beyotime Biotechnology (Shanghai, China). Recombinant human transforming growth factor-
β (TGF-
β) was provided by PeproTech (Rocky Hill, USA). MitoSOX Deep Red was purchased from Invitrogen (New York, USA). The following antibodies for immunohistochemistry and western blotting were used:
sirtuin 1 (SIRT1), NOX4,
E-cadherin,
superoxide dismutase 2 (SOD2), and
sirtuin 3 (SIRT3) antibodies, which were purchased from Proteintech (San Diego, USA). Other antibodies were from Abcam (Cambridge, UK):
collagen I,
collagen III, fibronectin (FN), total OXPHOS complexes, and
4-hydroxynonenal (4HNE). Anti-alpha smooth muscle actin (
α-SMA) antibody and
anti-GAPDH antibody were obtained from Sigma (St. Louis, MO, USA) and Cell Signaling Technology (Boston, MA, USA), respectively. All other chemicals were of analytical grade.
Liao X., Lv X., Zhang Y., Han Y., Li J., Zeng J., Tang D., Meng J., Yuan X., Peng Z., Tao L, & Xie Y. (2022). Fluorofenidone Inhibits UUO/IRI-Induced Renal Fibrosis by Reducing Mitochondrial Damage. Oxidative Medicine and Cellular Longevity, 2022, 2453617.